Who Paid My Doc
Steffan Schulz
Rheumatology Philadelphia, PA
NPI 1316154487 CMS profile 59802
3400 Civic Center Blvd, 1St Floor, Philadelphia, PA 19104
General payments
$0
Research payments
$0
Ownership & investment interest
$0
The CMS Open Payments record contains no reported payments to Steffan Schulz of Philadelphia, PA.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
Prescribing to Medicare patients
Part D · data year 2024 · 47 drugsPart D claims
3,409
Drug cost
$2,820,180
Branded share of claims
28.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Humira(Cf) Pen Adalimumab | Brand | 96 | $1,019,932 | |
| Enbrel Sureclick Etanercept | Brand | 58 | $474,631 | |
| Benlysta Belimumab | Brand | 75 | $330,014 | |
| Humira Pen Adalimumab | Brand | 25 | $250,969 | |
| Gamunex-C Immune Globul G/Gly/Iga Avg 46 | Brand | 13 | $182,838 | |
| Humira(Cf) Adalimumab | Brand | 11 | $131,295 | |
| Rinvoq Upadacitinib | Brand | 20 | $126,253 | |
| Orencia Abatacept/Maltose | Brand | 17 | $73,815 | |
| Cimzia (2 Pack) Certolizumab Pegol | Brand | 12 | $63,459 | |
| Hadlima(Cf) Pushtouch Adalimumab-Bwwd | Brand | 25 | $53,478 |
The 10 drugs with the highest cost, of 47 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 11 billing codesPaid by Medicare
$37,482
Medicare patients
202
Services billed
637
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 66% | |
| Depression | 32% | |
| Chronic kidney disease | 31% | |
| Diabetes | 30% | |
| Ischemic heart disease | 28% | |
| Osteoporosis | 24% | |
| Atrial fibrillation | 18% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Other Rheumatology in Pennsylvania
Related records
Rheumatology in Pennsylvania
Practitioners in the same specialty and state, ranked by reported value.
All Rheumatology
Everyone recorded under this specialty, nationwide.
Doctors in Pennsylvania
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.